Caption Management’s RAPT Therapeutics RAPT Stock Holding History

Caption Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-109,500	Closed	-$3.71M	–	1970
2025 Q4	$3.71M	Buy	+109,500	New	+$3.4M	0.03%	604
2025 Q1	–	Sell	-15,625	Closed	-$198K	–	1946
2024 Q4	$198K	Buy	+15,625	New	+$198K	﹤0.01%	1279
2024 Q3	–	Sell	-88	Closed	-$2.13K	–	1539
2024 Q2	$2.13K	Buy	+88	New	+$4.07K	﹤0.01%	1107
2022 Q3	–	Sell	-5,563	Closed	-$812K	–	1785
2022 Q2	$812K	Buy	+5,563	New	+$741K	0.01%	948
2022 Q1	–	Sell	-4,038	Closed	-$1.19M	–	1854
2021 Q4	$1.19M	Sell	4,038 -525	-12%	-$140K	0.01%	981
2021 Q3	$1.13M	Sell	4,563 -31,262	-87%	-$8.26M	0.01%	983
2021 Q2	$9.11M	Buy	+35,825	New	+$6.69M	0.12%	217

Caption Management's RAPT Position: Q4 2024 in Review

Caption Management sold out of RAPT Therapeutics (RAPT) in Q4 2024, closing a stake of 8,931 shares — an estimated $113K sold.

Caption Management first reported a position in RAPT in Q2 2021 and held it in 6 quarters. The position peaked at $13.4M in Q2 2021. 91 funds tracked by Wall St. Rank hold RAPT as of Q4 2024.

Caption Management reported no remaining RAPT Therapeutics position as of Q4 2024 after selling out during the quarter.
Caption Management sold 8,931 RAPT Therapeutics shares in Q4 2024, an estimated $113K.
Caption Management first reported a position in RAPT Therapeutics in Q2 2021 and held it in 6 quarters.
Caption Management's RAPT Therapeutics position peaked at $13.4M in Q2 2021.
91 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2024.

Based on Caption Management's 13F filing for Q4 2024, filed 14 Feb 2025.